Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| ALEXION PHARMACEUTICALS | 1 | 6 | +0,97 % | ||
| REGENERON PHARMACEUTICALS | 1 | 3 | +2,14 % | ||
| RA PHARMACEUTICALS | - | 29 | 0,00 % | ||
| GILEAD SCIENCES | - | 27 | +1,46 % | ||
| AKCEA THERAPEUTICS | - | 13 | +1,09 % | ||
| PUMA BIOTECHNOLOGY | - | 10 | -1,31 % | ||
| NEKTAR THERAPEUTICS | - | 8 | +5,82 % | ||
| CLOVIS ONCOLOGY | - | 8 | +5,37 % | ||
| BLUEBIRD BIO | - | 8 | -2,22 % | ||
| FIVE PRIME THERAPEUTICS | - | 8 | +3,76 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| So | Pfizer takes aim at a flagship franchise at Sanofi and Regeneron - and scores a few direct hits | 1 | Endpoints News | ||
| So | Stealth BioTherapeutics Does The Deal With Alexion, And Other Headlines: The Good, Bad And Ugly Of Biopharma | 6 | Seeking Alpha | ||
| Sa | Better Buy: Gilead Sciences vs. Johnson & Johnson | 41 | The Motley Fool | ||
| Sa | Flexion: Buying Before And After ZILRETTA's PDUFA | 1 | Seeking Alpha | ||
| Sa | Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo | 1.244 | Business Wire | Data presented at EADV demonstrate continued improvement in repigmentation of vitiligo lesions upon longer treatment duration with ruxolitinib cream
Incyte (Nasdaq:INCY) today announces positive... ► Artikel lesen | |
| Sa | Adverum Biotechnologies, Inc.: Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC ... | 1 | GlobeNewswire (USA) | ||
| Fr | HEXO, ZEN and LXRX among after hours movers | 4 | Seeking Alpha | ||
| Fr | Retrophin, Inc.: Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019 | 1 | GlobeNewswire (USA) | ||
| Fr | Apellis Pharmaceuticals, Inc.: Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week ... | 1 | GlobeNewswire (USA) | ||
| Fr | ProQR Therapeutics (PRQR) Sepofarsen Phase 1/2 Trial Topline Results - Slideshow | - | Seeking Alpha | ||
| Fr | Here's Why Aerie Pharmaceuticals Rose as Much as 21.8% Today | 2 | The Motley Fool | ||
| Fr | Mid-Day Market Update: Crude Oil Up 1.5%; Aclaris Therapeutics Shares Jump | 5 | Benzinga.com | ||
| Fr | Horizon Therapeutics' Phase 3 trial finds 'significant benefit' of teprotumumab | 1 | Seeking Alpha | ||
| Fr | Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn | 8 | FiercePharma | ||
| Fr | Court green-lights Clovis case after detailing evidence the board 'ignored red flags' on false safety and efficacy data | 5 | Endpoints News | ||
| Fr | Northwest Bio still hanging on; Five Prime's latest round of layoffs claims 70 | 1 | Endpoints News | ||
| Fr | FibroGen, Inc: Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented ... | 3 | GlobeNewswire (USA) | ||
| Fr | Long term data echo safety profile of Gilead, Galapagos' potential blockbuster JAK inhibitor | 16 | Endpoints News | ||
| Fr | Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019 | 2 | GlobeNewswire (USA) | ||
| Fr | Seattle Genetics Up More Than 20% in 3 Months: Here's Why | 1 | Zacks |
Seite:
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
